nach oben

Drug Safety

Erschienen in:

01.02.2009 | Original Research Article

Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac Arrest

An Observational Study in Italy Using Case-Control, Case-Crossover and Case-Time-Control Designs

verfasst von: Dr Antonella Zambon, Hernan Polo, Paolo Contiero, Giovanni Corrao

Erschienen in: Drug Safety | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Objective: To compare the effect of macrolide and fluoroquinolone antibacterials on the onset of ventricular arrhythmia and cardiac arrest using three different observational designs.

Methods: A population-based case-control study was performed by linking automated databases from the Varese Province of Italy. Cases were all subjects who experienced ventricular arrhythmia or cardiac arrest from July 1998 to December 2003. For each case, up to ten controls were randomly selected after matching for sex, age, practitioner and date of arrhythmia onset. The use of macrolides and fluoroquinolones during two time windows denoted as recent and referent intervals was ascertained. Odds ratios were estimated using case-control, case-crossover and case-time-control approaches.

Results: 1275 cases and 9189 controls met the inclusion criteria. Adjusted odds ratios (and corresponding 95% CIs) associated with recent exposure to macrolides were 2.13 (1.34, 3.39), 1.70 (0.88, 3.26) and 1.62 (0.78, 3.34) by using case-control, case-crossover and case-time-control designs, respectively. The corresponding estimates for fluoroquinolones were 3.58 (2.51, 5.12), 1.98 (1.19, 3.29) and 1.59 (0.88, 2.87), respectively.

Conclusions: Three observational study designs each using entirely different sets of controls consistently showed that recent use of macrolide and fluoro-quinolone antibacterials may be associated with increased risk of ventricular arrhythmia and cardiac arrest.

Viskin S, Justo D, Halkin A, et al. Long QT syndrome caused by noncardiac drugs. Progr Cardiovasc Dis 2002; 45: 415–27

De Ponti F, Poluzzi E, Cavalli A, et al. Safety of non-arrhythmic drugs that prolong the QT interval or induce torsade de pointes. Drug Saf 2002; 25: 263–86PubMedCrossRef

Clark DW, Layton D, Wilton LV, et al. Profiles of hepatic and dysrhythmic cardiovascular events following use of fluoroquinolone antibacterials: experience from large cohorts from the Drug Safety Research Unit Prescription-Event Monitoring database. Drug Saf 2001; 24: 1143–54PubMedCrossRef

De Bruin ML, Hoes AW, Leufkens HG. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias. Am J Cardiol 2003; 91: 59–62PubMedCrossRef

Ray WA, Murray KT, Meredith S, et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089–96PubMedCrossRef

Corrao G, Botteri E, Bagnardi V, et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Saf 2005; 14: 31–40PubMedCrossRef

Bagnardi V, Botteri E, Corrao G. Empirical-Bayes adjustment for multiple results in post-marketing drug safety surveillance with application to antibacterials and arrhythmia. J Clin Epidemiol 2006; 59: 1162–8PubMedCrossRef

Corrao G, Botteri E, Bertù L, et al. Exploring the effect of transient exposure on the risk of acute events by means of time-window designs: an application to fluoroquinolone antibacterials and arrhythmia. Pharmacoepidemiol Drug Saf 2006; 15: 31–7PubMedCrossRef

Suissa S. Pharmacoepidemiology overview. In: Gail MH, Benichou J, editors. Encyclopedia of epidemiologic methods. New York: John Wiley & Sons, 2000: 702–12

10.

Smeeth L, Donnan PT, Cook DG. The use of primary care databases: case-control and case-only designs. Fam Pract 2006; 23: 597–604PubMedCrossRef

11.

Maclure M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 1991; 113: 144–53

12.

Suissa S. The case-time-control design. Epidemiology 1995; 6: 248–53PubMedCrossRef

13.

Hernandez-Diaz S, Hernan MA, Meyer K, et al. Case-crossover and case-time-control designs in birth defects epidemiology. Am J Epidemiol 2003; 158: 385–91PubMedCrossRef

14.

Meyer KA, Williams P, Hernandez-Diaz S, et al. Smoking and the risk of oral clefts: exploring the impact of study designs. Epidemiology 2004; 15: 671–8PubMedCrossRef

15.

Schneider MF, Gange SJ, Margolick JB, et al. Application of case-crossover and case-time-control study designs in analyses of time-varying predictors of T-cell homeostasis failure. Ann Epidemiol 2005; 15: 137–44PubMedCrossRef

16.

Corrao G, Zambon A, Faini S, et al. Short-acting inhaled beta-2-agonists increased the mortality from chronic obstructive pulmonary disease in observational designs. J Clin Epidemiol 2005; 58: 92–7PubMedCrossRef

17.

Staffa JA, Jones JK, Gable CB, et al. Risk of selected serious cardiac events among new users of antihistamines. Clin Ther 1995; 17: 1062–77PubMedCrossRef

18.

Singh SN, Patrick J. Antiarrhythmic drugs. Curr Treat Options Cardiovasc Med 2004; 6: 357–64PubMedCrossRef

19.

Breslow NE, Day NE. Statistical methods in cancer research. Volume I: the analysis of case-control studies. IARC Scientific Publications No. 32. Lyon: International Agency for Research on Cancer, 1980

20.

Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433–7PubMed

21.

Greenland S, Gustafson P. Accounting for independent nondifferential misclassification does not increase certainty that an observed association is in the correct direction. Am J Epidemiol 2006; 164(1): 63–8PubMedCrossRef

22.

Shaffer D, Singer S, Korvick J, et al. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002; 35: 197–200PubMedCrossRef

23.

Matsunaga N, Oki Y, Prigollini A. A case of QT-interval prolongation precipitated by azithromycin. N Z Med J 2003; 116(1185): U666PubMed

24.

Smeeth L, Thomas SL, Hall AJ, et al. Risk of myocardial infarction and stroke after acute infection or vaccination.

25.

Salas M, Hofman A, Strieker BHC. Confounding by indication: an example of variation in the use of epidemiologic terminology. Am J Epidemiol 1999; 149: 981–3PubMedCrossRef

26.

Zabel M, Hohnloser SH, Behrens S, et al. Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol 1997; 8: 1148–58PubMedCrossRef

27.

Antzelevitch C. Cellular basis and mechanism underlying normal and abnormal myocardial repolarization and arrhythmogenesis. Ann Med 2004; 36 Suppl. 1: 5–14CrossRef

28.

Greenland S. Confounding and exposure trend in casecrossover and case-time-control designs. Epidemiology 1996; 7: 321–7

29.

Suissa S. The case-time-control design: further assumptions and conditions. Epidemiology 1998; 9: 441–5PubMedCrossRef

Titel: Effect of Macrolide and Fluoroquinolone Antibacterials on the Risk of Ventricular Arrhythmia and Cardiac Arrest
An Observational Study in Italy Using Case-Control, Case-Crossover and Case-Time-Control Designs
verfasst von: Dr Antonella Zambon
Hernan Polo
Paolo Contiero
Giovanni Corrao
Publikationsdatum: 01.02.2009
Verlag: Springer International Publishing
Erschienen in: Drug Safety / Ausgabe 2/2009
Print ISSN: 0114-5916
Elektronische ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200932020-00008

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Hepatotoxicity Associated with Long-versus Short-Course HIV-Prophylactic Nevirapine Use

A Strategy for Regulatory Action When New Adverse Effects of a Licensed Product Emerge

Risk Management of Medicines and Compensation for Harm

Examining the Tolerability of the Non-Sedating Antihistamine Desloratadine

Defining ‘Signal’ and its Subtypes in Pharmacovigilance Based on a Systematic Review of Previous Definitions

Drug-versus-Drug Adverse Event Rate Comparisons